CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
In ovarian cancer, inactivation of the CCDC6 protein signals a defect in DNA repair, known as HRD. This finding might expand the pool of patients, including those who are BRCA WT, who can receive PARP inhibitors, significantly broadening access to this targeted, life-extending therapy.
Institutions
- University of Parma (IT)
- University of Molise (IT)
- Agostino Gemelli University Polyclinic (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- University Hospitals Parma Medical Center (US)
- Istituto Dermopatico dell'Immacolata (IT)
- Federico II University Hospital (IT)
- Institute for Experimental Endocrinology and Oncology (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- IRCCS Humanitas Research Hospital (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0455
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05